TD Asset Management Inc Buys 44,770 Shares of DexCom, Inc. $DXCM

TD Asset Management Inc grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 16.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 320,798 shares of the medical device company’s stock after buying an additional 44,770 shares during the period. TD Asset Management Inc’s holdings in DexCom were worth $21,586,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Andra AP fonden acquired a new position in DexCom during the second quarter valued at approximately $26,000. Twin Peaks Wealth Advisors LLC acquired a new position in shares of DexCom in the 2nd quarter valued at $26,000. SJS Investment Consulting Inc. increased its position in shares of DexCom by 4,800.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after buying an additional 384 shares in the last quarter. Financial Consulate Inc. acquired a new stake in DexCom during the 3rd quarter worth $29,000. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in DexCom during the second quarter worth about $45,000. 97.75% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on DXCM. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 16th. Mizuho raised their target price on shares of DexCom from $78.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, February 13th. Argus reduced their price target on shares of DexCom from $100.00 to $90.00 and set a “buy” rating for the company in a report on Friday, November 7th. Robert W. Baird set a $87.00 price objective on shares of DexCom in a research report on Friday, February 13th. Finally, Barclays reiterated an “underweight” rating and set a $72.00 target price (up from $71.00) on shares of DexCom in a report on Friday, February 13th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average target price of $85.18.

DexCom Stock Down 1.3%

DexCom stock opened at $73.43 on Friday. The company has a fifty day simple moving average of $70.24 and a 200 day simple moving average of $69.15. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98. The company has a market cap of $28.26 billion, a P/E ratio of 34.97, a price-to-earnings-growth ratio of 1.43 and a beta of 1.49.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.03. The company had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.DexCom’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.45 EPS. Research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.